We note with interest comments by Einarson et al and Olfson and Marcus. Einarson et al raised questions about the Abstract. We believe that the Abstract is consistent with data presented in the article, and specific details were omitted because of space limitations. In response to the questions raised, we offer the following comments:
First, the rates of small for gestational age (SGA) in our sample may have been lower than what would have been expected for a population; this, however, should not invalidate or detract from our findings that the proportion of propensity score–matched infants of depressed mothers treated with SSRIs was significantly greater than for infants of mothers in the depressed or control groups. We used an American standard reference for SGA1 and our sample from British Columbia did not have the same incidence of SGA. Moreover, we used the same standard for the treatment and comparison groups and the use of an American standard should not bias the estimate of the difference. Why our infants during the study period would be heavier at birth remains to be determined.
Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal Risks of Maternal Treatment With Mood Stabilizers—Reply. Arch Gen Psychiatry. 2007;64(7):867–868. doi:10.1001/archpsyc.64.7.867